JP2016519107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519107A5 JP2016519107A5 JP2016507634A JP2016507634A JP2016519107A5 JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5 JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5
- Authority
- JP
- Japan
- Prior art keywords
- hypoxia
- predetermined value
- cancer
- degree
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000007954 hypoxia Effects 0.000 claims 5
- 238000012879 PET imaging Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361810643P | 2013-04-10 | 2013-04-10 | |
| US61/810,643 | 2013-04-10 | ||
| PCT/US2014/033491 WO2014169035A1 (en) | 2013-04-10 | 2014-04-09 | Predictive and response biomarker for th-302 anti-cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519107A JP2016519107A (ja) | 2016-06-30 |
| JP2016519107A5 true JP2016519107A5 (enExample) | 2017-06-01 |
Family
ID=51689977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507634A Pending JP2016519107A (ja) | 2013-04-10 | 2014-04-09 | Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20160296538A1 (enExample) |
| EP (1) | EP2983591A4 (enExample) |
| JP (1) | JP2016519107A (enExample) |
| WO (1) | WO2014169035A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| CN107427515B (zh) | 2014-12-03 | 2021-11-16 | 奥克兰联合服务有限公司 | 用于治疗癌症的激酶抑制剂前药 |
| US11504075B2 (en) * | 2017-12-20 | 2022-11-22 | University Health Network | System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| EP4509127A4 (en) | 2022-04-15 | 2026-07-15 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR |
| EP4529926A4 (en) | 2022-05-23 | 2026-07-01 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4674418A1 (en) | 2023-02-27 | 2026-01-07 | Ascentawits Pharmaceuticals, Ltd. | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method |
| EP4755396A1 (en) | 2023-07-28 | 2026-06-10 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
| CN121985960A (zh) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20070117784A1 (en) * | 2005-03-04 | 2007-05-24 | Novacea, Inc. | Treatment of hyperproliferative diseases with anthraquinones |
| WO2010048330A1 (en) * | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| AU2011276590A1 (en) * | 2010-06-28 | 2013-01-31 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| RU2597844C2 (ru) * | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
| WO2012008860A2 (en) * | 2010-07-16 | 2012-01-19 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
-
2014
- 2014-04-09 US US14/783,776 patent/US20160296538A1/en not_active Abandoned
- 2014-04-09 WO PCT/US2014/033491 patent/WO2014169035A1/en not_active Ceased
- 2014-04-09 JP JP2016507634A patent/JP2016519107A/ja active Pending
- 2014-04-09 EP EP14783066.5A patent/EP2983591A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| IN2015DN00450A (enExample) | ||
| EA201591290A2 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| JP2013536236A5 (enExample) | ||
| PL3762015T3 (pl) | Guselkumab do stosowania w leczeniu choroby leśniowskiego-crohna ze schematem dawkowania | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| JP2014201591A5 (enExample) | ||
| JP2019513151A5 (enExample) | ||
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| Estenkova et al. | About the SPA and resort-based treatment of the patients with oncological diseases | |
| CN302191919S (zh) | 医用x射线乳腺摄影系统 | |
| Yamada | Febrile neutropenia and peripheral nerve injuries: 3 case reports | |
| CN302536694S (zh) | 病人用界面组件 | |
| Yu et al. | CLINICAL INVESTIGATION OF THERAPEUTIC EFFECT OF HUO ZHEN AND HERBAL FUMIGANT IN TREATING ARTHRALGIA SYNDROME | |
| Davies | Acquired resistance in non-small cell lung cancer: case report | |
| Stepanov et al. | Experience of Vasonat usage in treatment of patients with chronic toxic hepatitis | |
| Kilincalp | Azathioprine/corticosteroid |